Published in N Engl J Med on August 31, 2013
Hokusai Study in Pediatric Patients With Confirmed Venous Thromboembolism (VTE) | NCT02798471
Effects of Edoxaban on Platelet Aggregation (Edoxaban) | NCT05122455
Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis. Circulation (2015) 1.66
Direct oral anticoagulants: integration into clinical practice. Postgrad Med J (2014) 1.40
Edoxaban versus warfarin for venous thromboembolism. N Engl J Med (2014) 1.06
Measurement of non-VKA oral anticoagulants versus classic ones: the appropriate use of hemostasis assays. Thromb J (2014) 1.05
Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc (2014) 1.00
Guidance for the treatment of deep vein thrombosis and pulmonary embolism. J Thromb Thrombolysis (2016) 0.96
Treatment options for venous thromboembolism: lessons learnt from clinical trials. Thromb J (2014) 0.95
Management dilemmas in acute pulmonary embolism. Thorax (2013) 0.93
The effect of rifampin on the pharmacokinetics of edoxaban in healthy adults. Clin Drug Investig (2015) 0.91
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment. J Thromb Thrombolysis (2016) 0.91
Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood (2014) 0.90
Direct Oral Anticoagulants Use in Antiphospholipid Syndrome: Are These Drugs an Effective and Safe Alternative to Warfarin? A Systematic Review of the Literature. Curr Rheumatol Rep (2016) 0.90
Edoxaban population pharmacokinetics and exposure-response analysis in patients with non-valvular atrial fibrillation. Eur J Clin Pharmacol (2014) 0.89
Sex differences in patients receiving anticoagulant therapy for venous thromboembolism. Medicine (Baltimore) (2014) 0.86
The evolution of anticoagulant therapy. Blood Transfus (2015) 0.86
Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost (2016) 0.86
Edoxaban: an update on the new oral direct factor Xa inhibitor. Drugs (2014) 0.86
Which patients with venous thromboembolism should receive non-vitamin K antagonist oral anticoagulants? The majority. Blood Transfus (2015) 0.85
Phase III trials of new oral anticoagulants in the acute treatment and secondary prevention of VTE: comparison and critique of study methodology and results. Adv Ther (2014) 0.85
Pharmacokinetics and Pharmacodynamics of Edoxaban, a Non-Vitamin K Antagonist Oral Anticoagulant that Inhibits Clotting Factor Xa. Clin Pharmacokinet (2016) 0.85
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events. Ther Clin Risk Manag (2015) 0.84
The role of factor Xa inhibitors in venous thromboembolism treatment. Vasc Health Risk Manag (2015) 0.84
Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Adv Hematol (2015) 0.84
Venous thromboembolism in the elderly: efficacy and safety of non-VKA oral anticoagulants. Thromb J (2014) 0.84
Considerations for long-term anticoagulant therapy in patients with venous thromboembolism in the novel oral anticoagulant era. Vasc Health Risk Manag (2016) 0.83
UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. PLoS One (2015) 0.83
New oral anticoagulants and the cancer patient. Oncologist (2013) 0.83
Cardiovascular outcomes during treatment with dabigatran: comprehensive analysis of individual subject data by treatment. Vasc Health Risk Manag (2013) 0.82
New oral anticoagulants for the treatment of venous thromboembolism: understanding differences and similarities. Drugs (2014) 0.82
Anticoagulant Treatment of Deep Vein Thrombosis and Pulmonary Embolism: The Present State of the Art. Front Cardiovasc Med (2015) 0.82
Intracranial hemorrhage risk with the new oral anticoagulants: a systematic review and meta-analysis. J Neurol (2014) 0.82
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists. Leukemia (2016) 0.81
Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res (2015) 0.81
Recent advances in the management of pulmonary embolism: focus on the critically ill patients. Ann Intensive Care (2016) 0.81
Pharmacokinetic and pharmacodynamic evaluation of rivaroxaban: considerations for the treatment of venous thromboembolism. Thromb J (2014) 0.81
Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag (2015) 0.81
Vitamin K antagonist use: evidence of the difficulty of achieving and maintaining target INR range and subsequent consequences. Thromb J (2016) 0.81
Edoxaban: A Comprehensive Review of the Pharmacology and Clinical Data for the Management of Atrial Fibrillation and Venous Thromboembolism. Cardiol Ther (2016) 0.80
Expanding use of new oral anticoagulants. F1000Prime Rep (2014) 0.80
Management of Venous Thromboembolisms: Part I. The Consensus for Deep Vein Thrombosis. Zhonghua Minguo Xin Zang Xue Hui Za Zhi (2016) 0.80
Use of novel oral anticoagulant agents in venous thromboembolism. Cardiovasc Diagn Ther (2016) 0.79
Which oral anticoagulant to use: factor Xa inhibitor or thrombin inhibitor? Natl Med J India (2014) 0.79
Venous thromboembolism in Latin America: a review and guide to diagnosis and treatment for primary care. Clinics (Sao Paulo) (2016) 0.79
Non-vitamin K antagonist oral anticoagulants and the treatment of venous thromboembolism in cancer patients: a semi systematic review and meta-analysis of safety and efficacy outcomes. PLoS One (2014) 0.79
Population pharmacokinetics of edoxaban in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism-the Hokusai-VTE phase 3 study. Br J Clin Pharmacol (2015) 0.79
Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review. J Thromb Thrombolysis (2015) 0.79
Safe and effective use of rivaroxaban for treatment of cancer-associated venous thromboembolic disease: a prospective cohort study. J Thromb Thrombolysis (2016) 0.79
Length of Stay Comparison between Rivaroxaban and Warfarin in the Treatment of Pulmonary Embolism: Results from a Real-World Observational Cohort Study. Thrombosis (2015) 0.78
Risk of Fatal Bleeding in Episodes of Major Bleeding with New Oral Anticoagulants and Vitamin K Antagonists: A Systematic Review and Meta-Analysis. PLoS One (2015) 0.78
The new oral anticoagulants for the treatment of venous thromboembolism: a new paradigm shift in antithrombotic therapy. Curr Ther Res Clin Exp (2014) 0.78
Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol (2015) 0.78
The new era of anticoagulation. Surg Neurol Int (2016) 0.78
Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant. Thromb J (2017) 0.78
Management of venous thromboembolism: an update. Thromb J (2016) 0.78
A rapid pro-hemostatic approach to overcome direct oral anticoagulants. Nat Med (2016) 0.77
Primary prevention and treatment of venous thromboembolic events in patients with gastrointestinal cancers - Review. World J Gastrointest Oncol (2016) 0.77
Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Edoxaban (Savaysa): A Factor Xa Inhibitor. P T (2015) 0.77
Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review. Vasc Health Risk Manag (2014) 0.77
XALIA: rationale and design of a non-interventional study of rivaroxaban compared with standard therapy for initial and long-term anticoagulation in deep vein thrombosis. Thromb J (2014) 0.77
Admission rates for emergency department patients with venous thromboembolism and estimation of the proportion of low risk pulmonary embolism patients: a US perspective. Clin Exp Emerg Med (2016) 0.77
Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. J Thromb Thrombolysis (2016) 0.77
Warfarin Therapy: Survey of Patients' Knowledge of their Drug Regimen. Malays J Med Sci (2014) 0.76
Hokusai-VTE: Edoxaban for the treatment of venous thromboembolism. Glob Cardiol Sci Pract (2013) 0.76
Measures of vitamin K antagonist control reported in atrial fibrillation and venous thromboembolism studies: a systematic review. BMJ Open (2014) 0.76
The Italian START-Register on Anticoagulation with Focus on Atrial Fibrillation. PLoS One (2015) 0.76
Edoxaban Exposure-Response Analysis and Clinical Utility Index Assessment in Patients With Symptomatic Deep-Vein Thrombosis or Pulmonary Embolism. CPT Pharmacometrics Syst Pharmacol (2016) 0.75
Risk-adapted management of acute pulmonary embolism: recent evidence, new guidelines. Rambam Maimonides Med J (2014) 0.75
Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol (2016) 0.75
Update on Anticoagulation: What the Interventional Radiologist Needs to Know. Semin Intervent Radiol (2016) 0.75
Edoxaban: an investigational factor xa inhibitor. P T (2014) 0.75
In intracranial artery stenosis, adding angioplasty and stenting to medical therapy increased stroke or death. Ann Intern Med (2014) 0.75
Perioperative venous thromboembolic disease and the emerging role of the novel oral anticoagulants: An analysis of the implications for perioperative management. Ann Card Anaesth (2015) 0.75
Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism. Ther Clin Risk Manag (2016) 0.75
DOACs - advances and limitations in real world. Thromb J (2016) 0.75
Edoxaban Was Effective for the Treatment of Deep Vein Thrombosis and Pulmonary Thromboembolism in a Cancer Patient with Antithrombin III Deficiency. Intern Med (2016) 0.75
Direct oral anticoagulants for the treatment of unprovoked venous thromboembolism: a meta-analysis of randomised controlled trials. Blood Transfus (2014) 0.75
Possible failure of novel direct-acting oral anticoagulants in management of pulmonary embolism: a case report. J Med Case Rep (2016) 0.75
The Potential Role of Edoxaban in Stroke Prevention Guidelines. Arrhythm Electrophysiol Rev (2014) 0.75
Extensive deep vein thrombosis treatment using fondaparinux and edoxaban: a case report. Thromb J (2016) 0.75
Cancer-associated thrombosis in Asia. Thromb J (2016) 0.75
Management of Venous Thromboembolism: Recent Advances in Oral Anticoagulation Therapy. Ann Pharmacother (2016) 0.75
New anticoagulants for the treatment of venous thromboembolism. J Bras Pneumol (2016) 0.75
Direct-Acting Oral Anticoagulants: Practical Considerations for Emergency Medicine Physicians. Emerg Med Int (2016) 0.75
How we treat bleeding associated with direct oral anticoagulants. Blood Transfus (2016) 0.75
Edoxaban. Hosp Pharm (2015) 0.75
Pulmonary embolism: new treatments for an old problem. Open Access Emerg Med (2016) 0.75
New oral pharmacotherapeutic agents for venous thromboprophylaxis after total hip arthroplasty. World J Orthop (2014) 0.75
Respiratory review of 2014: pulmonary thromboembolism. Tuberc Respir Dis (Seoul) (2014) 0.75
Reversal of direct oral anticoagulants in hemophilia treatment: ASH meeting 2015. Memo (2016) 0.75
Diffuse Alveolar Hemorrhage Associated with Edoxaban Therapy. Case Rep Crit Care (2016) 0.75
Effective management of venous thromboembolism in the community: non-vitamin K antagonist oral anticoagulants. Int J Gen Med (2016) 0.75
Theme 3: Non-invasive management of (recurrent) venous thromboembolism (VTE) and post thrombotic syndrome (PTS). Thromb Res (2015) 0.75
Successful use of rivaroxaban in postoperative deep vein thrombosis of the lower limb following instability with warfarin: a case report. J Med Case Rep (2016) 0.75
Edoxaban in venous thromboembolism and stroke prevention: an appraisal. Vasc Health Risk Manag (2016) 0.75
Use of novel oral anticoagulants for the treatment of venous thromboembolism and its considerations in Asian patients. Ther Clin Risk Manag (2014) 0.75
Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med (2012) 11.86
Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med (2010) 9.92
Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2013) 7.70
The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol (2003) 7.54
Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest (2008) 7.12
Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med (2013) 7.00
Outpatient versus inpatient treatment for patients with acute pulmonary embolism: an international, open-label, randomised, non-inferiority trial. Lancet (2011) 6.25
Antithrombotic therapy for venous thromboembolic disease: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest (2004) 5.96
Idarucizumab for Dabigatran Reversal. N Engl J Med (2015) 5.91
Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med (2010) 5.79
Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med (2004) 5.68
Fondaparinux for the treatment of superficial-vein thrombosis in the legs. N Engl J Med (2010) 5.65
Apixaban versus enoxaparin for thromboprophylaxis after hip replacement. N Engl J Med (2010) 5.59
Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet (2007) 5.41
European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace (2013) 5.16
Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med (2010) 5.06
Effectiveness of managing suspected pulmonary embolism using an algorithm combining clinical probability, D-dimer testing, and computed tomography. JAMA (2006) 4.75
Factor XI antisense oligonucleotide for prevention of venous thrombosis. N Engl J Med (2014) 4.58
Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med (2004) 4.52
Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2005) 4.46
Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med (2013) 4.43
Apixaban for extended treatment of venous thromboembolism. N Engl J Med (2012) 4.37
Residual thrombosis on ultrasonography to guide the duration of anticoagulation in patients with deep venous thrombosis: a randomized trial. Ann Intern Med (2009) 4.27
Pulmonary arterial hypertension: baseline characteristics from the REVEAL Registry. Chest (2009) 4.08
Below-knee elastic compression stockings to prevent the post-thrombotic syndrome: a randomized, controlled trial. Ann Intern Med (2004) 3.74
Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med (2007) 3.64
Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood (2002) 3.59
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med (2002) 3.51
An association between atherosclerosis and venous thrombosis. N Engl J Med (2003) 3.39
Apixaban versus enoxaparin for thromboprophylaxis after knee replacement (ADVANCE-2): a randomised double-blind trial. Lancet (2010) 3.29
The changing picture of patients with pulmonary arterial hypertension in the United States: how REVEAL differs from historic and non-US Contemporary Registries. Chest (2010) 3.02
Bidirectional relation between inflammation and coagulation. Circulation (2004) 3.00
Left bundle-branch block induced by transcatheter aortic valve implantation increases risk of death. Circulation (2012) 2.95
Apixaban or enoxaparin for thromboprophylaxis after knee replacement. N Engl J Med (2009) 2.90
Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double-blind placebo-controlled randomised trial. Lancet (2003) 2.86
Cost-effectiveness of Mohs Micrographic Surgery vs Surgical Excision for Basal Cell Carcinoma of the Face. Arch Dermatol (2006) 2.84
Facts and fiction of poor compliance as a cause of inadequate blood pressure control: a systematic review. J Hypertens (2004) 2.71
The optimal intensity of vitamin K antagonists in patients with mechanical heart valves: a meta-analysis. J Am Coll Cardiol (2003) 2.71
Progression from paroxysmal to persistent atrial fibrillation clinical correlates and prognosis. J Am Coll Cardiol (2010) 2.59
EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J (2013) 2.52
Venous thrombosis after long-haul flights. Arch Intern Med (2003) 2.50
Safe exclusion of pulmonary embolism using the Wells rule and qualitative D-dimer testing in primary care: prospective cohort study. BMJ (2012) 2.38
Updated European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace (2015) 2.35
Comparing the diagnostic performance of 2 clinical decision rules to rule out deep vein thrombosis in primary care patients. Ann Fam Med (2011) 2.34
Diagnostic strategies for excluding pulmonary embolism in clinical outcome studies. A systematic review. Ann Intern Med (2003) 2.33
The incidence of recurrent venous thromboembolism after treatment with vitamin K antagonists in relation to time since first event: a meta-analysis. Arch Intern Med (2003) 2.33
The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol (2005) 2.31
Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology (2005) 2.30
Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. J Arthroplasty (2008) 2.30
Clinical utility of D-dimer in patients with suspected pulmonary embolism and nondiagnostic lung scans or negative CT findings. Chest (2004) 2.30
Performance of 4 clinical decision rules in the diagnostic management of acute pulmonary embolism: a prospective cohort study. Ann Intern Med (2011) 2.28
The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol (2004) 2.26
Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J (2013) 2.21
Safely ruling out deep venous thrombosis in primary care. Ann Intern Med (2009) 2.16
Preoperative or postoperative start of prophylaxis for venous thromboembolism with low-molecular-weight heparin in elective hip surgery? Arch Intern Med (2002) 2.16
Direct thrombin inhibitors. N Engl J Med (2005) 2.15
Clinical features of paediatric pulmonary hypertension: a registry study. Lancet (2012) 2.13
Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev (2012) 2.09
Risk of deep vein thrombosis and pulmonary embolism in asthma. Eur Respir J (2012) 2.08
Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad TromboEmbolica venosa (RIETE) Registry. Circulation (2008) 2.00
Lipid lowering by simvastatin induces regression of human atherosclerotic lesions: two years' follow-up by high-resolution noninvasive magnetic resonance imaging. Circulation (2002) 2.00
Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1. Circ Res (2006) 1.95
Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary embolism. Arch Intern Med (2004) 1.92
Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J (2006) 1.84